

Tecentriq approved for small cell lung cancer

March 19 2019

(HealthDay)—Tecentriq (atezolizumab) has been approved by the U.S. Food and Drug Administration to treat adults with extensive-stage small cell lung cancer (ES-SCLC).

The drug has been approved as a first-line treatment for the disease, to be used in combination with the [chemotherapy drugs](#) carboplatin and etoposide.

Tecentriq was evaluated in a clinical study involving 403 adults who had received no prior chemotherapy, the FDA said in a news release.

Average survival for those who took the Tecentriq combination was 12.3 months, compared to 10.3 months among those who took the chemotherapy drugs and a placebo.

The most common side effects among the Tecentriq group were fatigue, nausea, temporary baldness, constipation and loss of appetite.

The newly approved [drug](#) is produced by Genentech, based in South San Francisco.

More information: The FDA has more about [this approval](#).

Copyright © 2019 [HealthDay](#). All rights reserved.

Citation: Tecentriq approved for small cell lung cancer (2019, March 19) retrieved 10 April 2024

from <https://medicalxpress.com/news/2019-03-tecentriq-small-cell-lung-cancer.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.